Janssen Submits Application to U.S. FDA to Expand Indication for DARZALEX ® (daratumumab) Combination Therapy for Patients with Newly Diagnosed Multiple Myeloma who are Transplant Ineligible

Source: Johnson and Johnson - Category: Pharmaceuticals Source Type: news